Genetic Technologies (GENE) rises 21% premarket after saying it has executed an agreement with a...

Genetic Technologies (GENE) rises 21% premarket after saying it has executed an agreement with a fifth PPO, allowing the company's BREVAGen test to be adjudicated "in network," where reimbursement is 25% higher and collection times are "materially shorter." (PR)